Mackenzie Financial
AUPH icon

Mackenzie Financial’s Aurinia Pharmaceuticals AUPH Stock Holding History

Mackenzie Financial’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,719
Closed -$118K – 1676
2025
Q3 		$118K Hold
10,719
– – ﹤0.01% 1617
2025
Q2 		$90.8K Hold
10,719
– – ﹤0.01% 1623
2025
Q1 		$86.2K Buy
+10,719
New +$86.8K ﹤0.01% 1596
2021
Q3 		– Sell
-27,877
Closed -$361K – 1436
2021
Q2 		$361K Buy
27,877
+574
+2% +$7.31K ﹤0.01% 1038
2021
Q1 		$355K Buy
27,303
+15,046
+123% +$218K ﹤0.01% 1000
2020
Q4 		$169K Buy
12,257
+407
+3% +$5.92K ﹤0.01% 1001
2020
Q3 		$175K Buy
+11,850
New +$172K ﹤0.01% 935

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mackenzie Financial's AUPH Position: Q4 2025 in Review

Mackenzie Financial sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2025, closing a stake of 10,719 shares — an estimated $118K sold.

Mackenzie Financial first reported a position in AUPH in Q3 2020 and held it in 7 quarters. The position peaked at $361K in Q2 2021. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

  • Mackenzie Financial reported no remaining Aurinia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Mackenzie Financial sold 10,719 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $118K.
  • Mackenzie Financial first reported a position in Aurinia Pharmaceuticals in Q3 2020 and held it in 7 quarters.
  • Mackenzie Financial's Aurinia Pharmaceuticals position peaked at $361K in Q2 2021.
  • 255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on Mackenzie Financial's 13F filing for Q4 2025, filed 18 Feb 2026.